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E-mail address: lars.nilsson@pubcare.uu.se (L.N.G.Intraneuronal punctate immunostaining in Alzheimer’s disease brain and amyloid-b precursor pro-
tein (APP) transgenic mice has been suggested to represent Ab, but this is somewhat controversial.
Here we show that both biochemical Ab levels and intraneuronal immunostaining are reduced in
APP transgenic mice when c-secretase is inhibited. Moreover, BACE-1 deﬁcient APP transgenic mice
show neither Ab production nor intraneuronal immunostaining. Our ﬁndings suggest that the punc-
tate immunostaining with APP antibodies is due to Ab that has accumulated inside neurons. Similar
type of intraneuronal Ab accumulation, which precedes senile plaque formation, may link Ab to tau-
opathy and neurodegeneration in Alzheimer’s disease pathogenesis.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Amyloid-b (Ab) aggregation leads to senile plaque formation, a
hallmark of Alzheimer’s disease (AD) neuropathology. The mecha-
nisms of Ab assembly have been extensively investigated in vitro,
but far less in the brain in vivo. Endoproteolysis of amyloid-b pre-
cursor protein (APP) and subsequent secretion of Ab into the inter-
stitial ﬂuid may lead to ﬁbril formation [1,2]. Ab could also remain
inside the cell following c-secretase cleavage, or be reinternalized
and generate Ab aggregates within neurons. Intraneuronal Ab has
been demonstrated by immunostaining in brain regions which la-
ter develop Ab plaque neuropathology in AD, mild cognitive
impairment (MCI) and Down syndrome [3,4]. Punctate intraneuro-
nal immunostaining has been shown to increase with age and to
diminish once senile plaques emerge in transgenic mice, in which
the process of Ab accumulation is easier to investigate. This sug-
gests a dynamic relationship between pools of Ab [5,6]. However,
intraneuronal Ab has only been demonstrated by histological tech-
niques. Thus the immunostaining could be due to APP or APP-frag-
ments which are far more abundant, especially in brains of young
APP transgenic mice. To decisively determine if Ab accumulates in-
side neurons we utilized a pharmacological and an independentchemical Societies. Published by E
Caring Sciences/Molecular
Väg 20, SE-751 85 Uppsala,
Nilsson).genetic approach to inhibit the activity of Ab-releasing secretases.
By quantifying the staining and measuring Ab levels we sought to
prove or refute an Ab-identity of the intraneuronal immunostain-
ing. Tg-ArcSwe mice [5], were administered a single dose of a
potent c-secretase inhibitor, or crossed with mice lacking murine
b-site APP-cleaving enzyme 1 (BACE-1). Brains were then investi-
gated with biochemical and immunohistochemical techniques.2. Materials and methods
2.1. Transgenic mice
Two-months-old tg-ArcSwe mice [5,7] were given a c-secretase
inhibitor or vehicle by oral gavage (BMS-299897, 300 lmol/kg at
10 ml/kg, Mw = 511.95 g/mol [8]) and sacriﬁced 6 h after a single
dose. The drug was dissolved in 0.1 M Meglumin [N-methyl-D-
glucamine (Sigma–Aldrich, St. Louis, MO)]. Tg-ArcSwe mice were
crossed with BACE-1 knockout mice [9], both of which had a
C57BL/6 background. BACE-1 was conﬁrmed with primers anneal-
ing at 616–637 and 870–849 in NC_000075.5. The targeted allele
was detected with primers located at 473–453 in AF335419.3
and 870–849 in NC_000075.5 and in the APP-transgene [5]. Ani-
mals were perfused with 0.9% (w/v) NaCl and the frontal cortex
separated at bregma level +1 mm [10]. Hemispheres were either
ﬁxed in 4% paraformaldehyde and prepared for histology [5], or
rapidly frozen and stored at 80 C and used for biochemistry.lsevier B.V. All rights reserved.
Fig. 1. Tg-ArcSwe mice treated with a c-secretase inhibitor. Two-months-old tg-ArcSwe mice were given a single dose of BMS-299897 (300 lmol/kg) or vehicle and killed at
6 h. (A) Decreased Ab and increased C99 in animals treated with c-secretase inhibitor (+) as compared to vehicle (). Western blots above dashed line (6% Tris–glycine gel)
with the N- and C-terminal APP antibodies 22C11 and CT695, and below dashed line (10–20% Tris–tricine gel) with 6E10. (B) Normalized C99/b-actin ratios were 10-fold
increased as compared to mice treated with vehicle (P < 0.001, n = 7). Differences in CT695-immunostaining in (C) non-transgenic mice, (D) tg-ArcSwe mice treated with
vehicle or (E) BMS-299897 reﬂect an increase and a redistribution of C-terminal APP-fragments as a result of c-secretase inhibition. Neoepitope-dependent intraneuronal Ab
staining with 82E1 in the CA1 region of hippocampus in mice treated with (F) vehicle or (G) c-secretase inhibitor. Inserts show staining above threshold (in red) used for
quantitative image analysis. (H) Reduced intraneuronal Ab immunoreactivity (35%, left) and frequency of granula (30%) in c-secretase inhibitor treated mice (P < 0.01,
n = 10), as compared to vehicle. (I) Reduced Ab1-40 (P < 0.01) and Ab1-42 ELISA levels (P < 0.05) in SDS-extracts (left y-axis), and Ab1-40 (P < 0.001) and Ab1-42 (P < 0.01)
levels in TBS-extracts (right y-axis) of tg-ArcSwe (n = 10) treated with c-secretase inhibitor. Scale bars measures: 350 lm (C–E) and 35 lm (F and G).
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Fig. 2. Western blot analyses of tg-ArcSwe mice with or without murine BACE-1.
SDS-extracts of two-months-old tg-ArcSwe mBACE/ mouse brain were devoid
of murine BACE-1, bAPPs (Sw192 antibody), C99 and Ab (6E10 antibody) when
analysed with SDS–PAGE and western blot. In contrast, mature APP (C-terminal APP
antibody CT695) was slightly increased in tg-ArcSwe mice that lacked the murine
BACE-1 gene.
O. Philipson et al. / FEBS Letters 583 (2009) 3021–3026 30232.2. Western blot
Brains were homogenized at 1:10 (w/v) in Tris-buffered saline
(TBS: 20 mM Tris, 137 mM NaCl, pH 7.6) and Complete (Roche,
Basel, Switzerland), with or without 2% (w/v) SDS, using a Dounce
homogenizer (10 strokes on ice), sonicated and centrifuged at
100,000g. Supernatants were analyzed with SDS–PAGE and wes-
tern blot for BACE-1 (Anti-BACE Ab-2; 1 lg/ml, Calbiochem,
Darmstadt, Germany), APP and APP-fragments including Ab with
antibodies 6E10 (0.2 lg/ml, epitope Ab3-8, Signet, Dedham, MA,
USA), 22C11 (20 ng/ml, epitope 66–81 in APP; Millipore, Billerica,
MA), CT695 (0.8 lg/ml, C-terminal APP; Zymed, San Francisco,
CA) and Sw192 antibody (0.1 lg/ml, neoepitope speciﬁc for b-
cleaved APP-Swe [11]), and secondary antibodies, 0.16 lg/ml,
anti-rabbit IgG-HRP or anti-mouse IgG/IgM-HRP (Pierce). Signals
were detected with SuperSignal (Pierce) and ECL-Hyperﬁlm (Amer-
sham) and analyzed by densitometry (sum of background sub-
tracted pixel values) using Kodak 1D Image Analysis Software.
Equal loading was veriﬁed with b-actin immunostaining.
2.3. Ab ELISA
Ninety-six well plates (Corning Inc., NY) were coated with C-
terminal neoepitope-speciﬁc Ab antibodies (anti-Ab40, 100 ng/
well or anti-Ab42, 200 ng/well, Agrisera, Umeå, Sweden [12]) at
+4 C for 12 h and blocked with 1% BSA in phosphate-buffered
NaCl, 0.15% Kathon (Rohm & Haas, Philadelphia, PA). Samples
and synthetic Arctic Ab (PolyPeptide Laboratories) were incubated
for 2 h at RT in sample buffer (PBS with 0.1% BSA, 0.05% Tween, and
0.15% Kathon) and then with biotinylated mAb1C3 (50 ng/well,
epitope Ab3-8, Mabtech, Nacka, Sweden [13]) for 2 h. Wells were
washed three times after each step (PBS with 0.1% Tween) and
incubated with streptavidine-coupled HRP (1:5000; Mabtech) for
1 h, K-blue aqueous substrate (ANL produkter, Älvsjö, Sweden)
and ﬁnally 1 M H2SO4. Plates were read at 450 nm.
2.4. Histology and image analysis
For immunohistochemistry [5], sections were incubated with
primary antibodies 82E1 (1 lg/ml, neoepitope Ab1-5; IBL, Ham-
burg, Germany), Ab40 (1 lg/ml Biosource, Camarillo, CA), Ab42
(2.5 lg/ml, Agrisera, Umeå, Sweden [12]) or CT695 (0.8 lg/ml,
Zymed, San Fransisco, CA) overnight at 4 C and with secondary
antibodies and NOVA red (both from Vector). Four coronal tissue
sections between Bregma 1.4 mm to 2.8 mm [10] from each
animal were analyzed blinded. Two photomicrographs of the pyra-
midal cell layer in the CA1 region of hippocampus from each sec-
tion were captured at 400 magniﬁcation (DXM1200F; Nikon
Instruments Inc., Melville, NY). Images were converted to grey-
scale, sharpened and processed with an auto threshold command
using custom-made macros to measure intraneuronal Ab immuno-
reactivity (Image Pro-Plus, Cybernetics, Silver Spring, MD). Thresh-
old intensity was kept constant, and the area of interest was
recorded as the percentage area stained per total tissue area cap-
tured, and presented as mean ± S.E.M. Statistical analyses were
done with unpaired Student’s t-test, since the data did not deviate
from Gaussian distribution (GraphPad, San Diego, CA).
3. Results
3.1. C-terminal APP-fragments were redistributed and quantitatively
increased by a c-secretase inhibitor
Two-months-old tg-ArcSwe mice were given a single dose of a
c-secretase inhibitor (BMS-299897, 300 lmol/kg) and killed 6 h
after administration. As expected [8], the level of C99 on westernblot was markedly increased in brains of tg-ArcSwe mice treated
with the c-secretase inhibitor (9.6 ± 0.4, n = 7) as compared to
vehicle (1.0 ± 0.1; mean ± S.E.M., n = 7), while levels of APP and
the N-terminal APP-fragment aAPPs were unchanged (Fig. 1A
and B). Immunostaining with a C-terminal APP antibody, CT695,
was decreased in cell bodies and enhanced at nerve endings in
mice treated with the c-secretase inhibitor (Fig. 1C–E).
3.2. Ab levels and intraneuronal staining were both reduced by the
c-secretase inhibitor
The antibody 82E1, with a neoepitope at the N-terminus of Ab,
gave a punctate immunostaining in pyramidal neurons of the hip-
pocampus and lower layers of the cerebral cortex (and located
intracellular as shown with confocal z-scan analysis; Supplemen-
tary Fig. 1). Intraneuronal Ab immunostaining was measured in
the CA1 region of the hippocampus, where staining is easy to quan-
tify. Image analysis revealed a 35% reduced area fraction occu-
pied by immunopositive punctate in c-secretase inhibitor treated
mice (65.9 ± 7.7%, mean ± S.E.M., n = 10), as compared to mice trea-
ted with vehicle (100.0 ± 6.0%, n = 10). The reduction was mainly
due to a lower frequency (30%) of inclusions (71.0 ± 7.2%,
n = 10), and mean size of grains changed very little (Fig. 1F–H).
Brains were also analyzed by direct extraction either in TBS or in
2% SDS (Fig. 1I). Ab1-40 levels, as measured by ELISA, was reduced
by 65% in the TBS soluble extract in c-secretase treated mice
(0.49 ± 0.10 pmol/g, n = 10) as compared to vehicle-treated mice
(1.33 ± 0.08 pmol/g; mean ± S.E.M., n = 10). Likewise the level of
Ab1-42 was decreased by 50% as compared to vehicle alone
(0.47 ± 0.08 pmol/g, n = 12 versus 0.93 ± 0.09 pmol/g; mean ±
S.E.M., n = 12). In SDS-extracts, the level of Ab1-40 was only
reduced by 25% (5.81 ± 0.28 pmol/g, n = 12) in animals treated
with c-secretase inhibitor as compared to control mice
(7.56 ± 0.41 pmol/g; mean ± S.E.M., n = 12). Similarly, the level of
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4.99 ± 0.48 pmol/g; mean ± S.E.M., n = 12, Fig. 1I).
3.3. Tg-ArcSwe mice without murine BACE-1 were devoid of
intraneuronal immunostaining
Tg-ArcSwe mice with or without murine BACE-1 were then
investigated, since the latter mice should not produce Ab. As
expected, brains of BACE-1 deﬁcient tg-ArcSwe mice did not
contain the N-terminal APP-fragment bAPPs (Sw192 [11]), C99Fig. 3. Tg-ArcSwe mice without mBACE-1 do not show intraneuronal immunostaining. F
and N) or without mBACE-1 (C, G, K, O), and non-transgenic mice (D, H, L, P). Pyramidal ne
in tg-ArcSwe with BACE-1, while those devoid of BACE-1 or non-transgenic mice lacked
The area at the tip of open arrows (A–D) is magniﬁed below (E–H). (I–L) Ab40- and (M–P
point to individual neurons with punctate intraneuronal immunostaining that are magni
P).or Ab on western blot (regardless of exposure time), while ma-
ture APP was increased as compared to tg-ArcSwe mice with
murine BACE-1 gene (Fig. 2). Immunostaining revealed a partic-
ularly strong punctate intraneuronal immunostaining in the
large pyramidal neurons of layer V in tg-ArcSwe with BACE-1,
but not in those devoid of BACE-1 or in non-transgenic mice.
A similar pattern of immunostaining was demonstrated with
three different antibodies, 82E1 and Ab40- and Ab42-speciﬁc,
recognizing neoepitopes in the N- and C-terminus of Ab, respec-
tively. Thus punctate intraneuronal immunostaining dependedigures illustrate four-months-old tg-ArcSwe mice with (A and B, E and F, I and J, M
urons in layer V of the cerebral cortex contained intraneuronal Ab immunoreactivity
such immunostaining. (A–H) 82E1 recognizes a neoepitope at the N-terminus of Ab.
) Ab42-speciﬁc antibodies recognize neoepitopes at the C-terminus. Arrows (in E–P)
ﬁed and turned clockwise below. Scale bars measure: 250 lm (A–D) and 60 lm (E–
O. Philipson et al. / FEBS Letters 583 (2009) 3021–3026 3025upon the presence of murine BACE-1 (Fig. 3 and Supplementary
Fig. 2).
4. Discussion
Pharmacological and genetic interventions in APP-processing
led to changes in intraneuronal punctate immunostaining that
closely followed biochemical Ab levels, but not levels of APP or
APP-fragments. This strongly suggests that Ab accumulates inside
neurons in brain, at least in tg-ArcSwe mice. The brains were ex-
tracted in TBS buffer to estimate soluble and presumably mainly
extracellular Ab, and directly in SDS to recover essentially all Ab
in young tg-ArcSwe mice [7]. C-terminal APP-fragments were
increased and Ab was decreased in response to an inhibitor of
c-secretase as expected [8]. The partial redistribution of C-terminal
APP-fragments is likely due to accumulation at nerve terminals
where APP is mainly processed [14]. Interestingly, following treat-
mentwith a c-secretase inhibitor, the frequency of punctate intran-
euronal immunostaining (30%) and the level of Ab in SDS-extracts
(25%, Ab1-40; 30%, Ab1-42) decreased to a similar extent,
while the level of Ab in TBS-extracts was more markedly reduced
(50–65%). The half-life of extracellular Ab in the interstitial ﬂuid
is short, 1–2 h [15]. The clearance of intraneuronal Ab aggregates
is likely somewhat slower. This could explain why the SDS-soluble
pool, containing both extra- and intraneuronal Ab, was only mod-
estly reduced by the c-secretase inhibitor. The punctate intraneuro-
nal Ab staining has been found in multivesicular bodies (MVB) in
AD brain [3] and transgenic mice [16], and possibly Ab begins to
aggregate inside intracellular vesicles. Here we did not investigate
different assembly states of Ab in the brain, since it was not the
aim of the study. Moreover, for practical reasons, immunohisto-
chemical estimates of intraneuronal Ab and biochemical measures
of Ab could not be assessed in identical brain regions. Intraneuronal
Ab immunostaining is however strong in pyramidal neurons in
cerebral cortex and hippocampus along the entire rostro-caudal
axis, and well reﬂects the expression pattern of the transgene [5].
We conclude that punctate intraneuronal staining is mainly
composed of Ab. It is unlikely to consist of holoAPP or APP-frag-
ments, since immunostaining with antibodies recognizing neoepi-
topes at the N- or the C-terminus in Ab depends upon BACE.
Immunostaining with antibody 82E1, which binds to the N-termi-
nus in Ab, could be due to intraneuronal C99. This interpretation is
consistent with C99 not being present in tg-ArcSwe+/ mBACE-
1/ mice, but inconsistent with staining by C-terminal Ab anti-
bodies and also with the experiments in which tg-ArcSwe mice
were treated with a c-secretase inhibitor. Those experiments
showed that punctate intraneuronal immunostaining and bio-
chemical Ab levels both decreased, while levels of C-terminal APP
cleavage fragments increased 10-fold. Thus intraneuronal
immunostaining with antibodies recognizing neoepitopes in Ab
can neither be APP nor fragments of APP (N- or C-terminal trun-
cated APP-fragments). It must be Ab.
Injection of Ab antibodies into the parenchyma has previously
been shown to induce a transient decline of intraneuronal immu-
nostaining, suggesting that a metabolic pool of intraneuronal Ab
exists [17]. In the present study, Ab production was inhibited by
two distinct noninvasive approaches and tissues were analyzed
with several neoepitope-speciﬁc Ab antibodies in biochemical
and immunohistochemical assays. Our ﬁndings provide strong evi-
dence that Ab begins to accumulate at intraneuronal locations, at
least in tg-ArcSwe mice. Membranes of intracellular vesicles, with
a low pH and sphingolipids, could serve as an advantageous milieu
and favor Ab aggregation. Interestingly intraneuronal Ab immuno-
staining is mainly in the soma, while Ab monomers are generated
at nerve terminals [14]. Perhaps Ab aggregates initially form in
synaptic intracellular vesicles and become exposed at the externalsurface of those vesicles. Ab, having undergone conformational
changes, could then directly interact with tau and facilitate its
detachment from microtubules and ﬁbrillization during retrograde
transport of MVB [18]. This would trigger neuronal dysfunctions
and pretangle formation.
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